Ignite Creation Date:
2024-05-05 @ 11:43 AM
Last Modification Date:
2024-10-26 @ 9:12 AM
Study NCT ID:
NCT00114062
Status:
TERMINATED
Last Update Posted:
2016-11-29
First Post:
2005-06-13
Brief Title:
Study to Treat Uveitis Associated Macular Edema
Sponsor:
Merck Sharp Dohme LLC
Organization:
Merck Sharp Dohme LLC
Study Overview
Official Title:
A Randomized Double-Masked Parallel Group Multi-Center Dose Ranging Pilot Study of Denufosol Tetrasodium INS37217 Intravitreal Injection in Subjects With Uveitis Associated Macular Edema
Status:
TERMINATED
Status Verified Date:
2016-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to determine whether denufosol tetrasodium INS37217 Intravitreal Injection is well tolerated and has the potential to treat uveitis associated macular edema
Detailed Description:
Denufosol tetrasodium INS37217 Intravitreal Injection may provide clinical benefit in treatment of uveitis associated macular edema UME by reducing retinal thickness as measured by OCT and possibly enabling recovery of vision loss associated with UME Denufosol tetrasodium may also reverse the fluid accumulation of UME
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None